Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Flex Pharma Inc    FLKS

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/20/2017 03/21/2017 03/22/2017 03/23/2017 03/24/2017 Date
4.18(c) 4.08(c) 4.06(c) 4.08(c) 4.03(c) Last
192 003 227 228 144 503 28 331 22 533 Volume
-1.88% -2.39% -0.49% +0.49% -1.23% Change
More quotes
Financials ($)
Sales 2017 2,43 M
EBIT 2017 -50,3 M
Net income 2017 -49,6 M
Debt 2017 -
Yield 2017 -
Sales 2018 7,42 M
EBIT 2018 -65,5 M
Net income 2018 -64,9 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 29,8x
Capi. / Sales2018 9,76x
Capitalization 72,4 M
More Financials
Company
Flex Pharma, Inc. operates as a biotechnology company, which engages in developing treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions.The company was founded by Christoph Westphal and Jennifer M. Cermak on February 26,... 
More about the company
Surperformance© ratings of Flex Pharma Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on FLEX PHARMA INC
03/23 FLEX PHARMA : Newly-Published Study Reinforces Efficacy Of HOTSHOT® In Preventin..
03/09 FLEX PHARMA : to Report Fourth Quarter and Full Year 2016 Results on March 8, 20..
03/08 FLEX PHARMA : Management's Discussion and Analysis of Financial Condition and Re..
03/08 FLEX PHARMA, INC. (NASDAQ : FLKS) Files An 8-K Results of Operations and Financi..
03/08 FLEX PHARMA, INC. : Results of Operations and Financial Condition (form 8-K)
03/08 FLEX PHARMA : reports 4Q loss
03/08 FLEX PHARMA : Reports Year End 2016 Financial Results
03/01 FLEX PHARMA : to Report Fourth Quarter and Full Year 2016 Results on March 8, 20..
02/23 FLEX PHARMA, INC. (NASDAQ : FLKS) Files An 8-K Regulation FD Disclosure
02/23 FLEX PHARMA, INC. : Regulation FD Disclosure, Financial Statements and Exhibits ..
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
Latest Tweets
03/22Flex Pharma (FLKS) Presents At Oppenheimer 27th Annual Healthcare Conference .. 
03/13Piper Jaffray Companies Reiterates $12.00 Price Target for Flex Pharma Inc $F.. 
03/11Flex Pharma’s $FLKS Buy Rating Reiterated at Jefferies Group LLC  
03/11Flex Pharma's buy rating reiterated at Jefferies Group LLC. $9.00 PT.  
03/11Jefferies Group Comments on Flex Pharma Inc’s FY2021 Earnings $FLKS  
More tweets
Qtime:13
News from SeekingAlpha
03/22 Flex Pharma (FLKS) Presents At Oppenheimer 27th Annual Healthcare Conference
03/08 Flex Pharma's (FLKS) CEO Christoph Westphal on Q4 2016 Results - Earnings Cal..
03/08 Midday Gainers / Losers
03/08 Flex Pharma meets Q4 revenue consensus, but slow HOTSHOT ramp disappoints inv..
03/08 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
Advertisement
Chart FLEX PHARMA INC
Duration : Period :
Flex Pharma Inc Technical Analysis Chart | FLKS | US33938A1051 | 4-Traders
Full-screen chart
Technical analysis trends FLEX PHARMA INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 17,8 $
Spread / Average Target 340%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Christoph H. Westphal Chairman, President & Chief Executive Officer
Katharine Lindemann Chief Operating Officer
John McCabe Chief Financial Officer
Thomas C. Wessel Chief Medical Officer
John Sculley Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
FLEX PHARMA INC-23.67%72
AMGEN, INC.13.36%122 060
CELGENE CORPORATION6.59%95 986
GILEAD SCIENCES, INC.-5.73%88 240
REGENERON PHARMACEUTIC..1.61%39 568
ACTELION LTD24.44%29 804
More Results